On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Biogen (BIIB) upgraded to Buy from Neutral at Mizuho with analyst Thomas Shrader saying he likes what he sees at Biogen again. 2. Prudential (PRU) upgraded to Buy from Neutral at Citi with analyst Suneet Kamath saying Prudential's current valuation does not give the company enough credit for the quality of its business mix. 3. Chevron (CVX) upgraded to Outperform from Neutral at Macquarie with analyst Iain Reid saying cost reduction efforts and new production volumes driving outstanding free cash generation, which should cover capex and the dividend at an oil price below $40/bbl from 2018 onward. 4. Energy Transfer Equity (ETE) upgraded to Buy from Neutral at Goldman Sachs with analyst Theodore Durbin saying he expects Energy Transfer Equity's above average distribution growth to be driven by an improving free cash flow profile. 5. Emerson (EMR) was upgraded to Outperform from Market Perform at Cowen and to Buy from Neutral at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.